ACADIA Pharmaceuticals Newsroom

Express News | ACADIA Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

ReutersMay 17 16:05 ET

Express News | ACADIA Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome

ReutersMay 15 09:05 ET

Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), ACADIA Pharmaceuticals (ACAD) and Disc Medicine (IRON)

TipRanksMay 12 22:10 ET

Cantor Picks 14 Undervalued Biotech Stocks Worth a Second Look

Seeking AlphaMay 12 11:00 ET

Results: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Yahoo FinanceMay 11 09:10 ET

Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $17 From $19, Maintains Perform Rating

ACADIA Pharmaceuticals (ACAD) has an average rating of outperform and price targets ranging from $13 to $39, according to analysts polled by Capital IQ. Price: 15.45, Change: +0.24, Percent Change: +1

MT NewswiresMay 10 10:01 ET

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Integer Holdings (ITGR) and ACADIA Pharmaceuticals (ACAD)

TipRanksMay 10 08:20 ET

ACADIA Pharmaceuticals Is Maintained at Neutral by B of A Securities

ACADIA Pharmaceuticals Is Maintained at Neutral by B of A Securities

Dow JonesMay 10 07:59 ET

ACADIA Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Yahoo FinanceMay 10 07:58 ET

Express News | B of A Securities Maintains Neutral on ACADIA Pharmaceuticals, Lowers Price Target to $22

BenzingaMay 10 07:48 ET

Express News | ACADIA Pharmaceuticals Inc : Guggenheim Cuts Target Price to $26 From $30

ReutersMay 10 06:30 ET

Neutral Outlook on ACADIA Pharmaceuticals Amidst Revenue Miss and Revised Penetration Forecasts

TipRanksMay 10 05:05 ET

Buy Rating for ACADIA Pharmaceuticals Based on Promising Drug Prospects and Financial Stability

TipRanksMay 10 01:27 ET

Express News | ACADIA Pharmaceuticals Inc : Oppenheimer Cuts Target Price to $17 From $19

ReutersMay 10 00:12 ET

Daybue Guidance Looks Achievable for Acadia, Neuren -- Market Talk

0011 GMT - Acadia Pharmaceuticals' target of $370 million-$420 million net sales of its Daybue treatment for Retts Syndrome looks achievable to Jefferies, despite a small miss in 1Q. In a research not

WSJMay 9 20:12 ET

Neuren Pharmaceuticals Partner Acadia Pharmaceuticals Posts US DAYBUE Sales of $75.9 Million

Neuren Pharmaceuticals (ASX:NEU) partner Acadia Pharmaceuticals (NASDAQ:ACAD) posted Q1 net sales of its DAYBUE treatment in the US of $75.9 million, below its guidance of $76 million to $82 million,

MT NewswiresMay 9 17:24 ET

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will participate at three upcoming investor conferences: Citizens JMP Life Sciences Conference Fireside Chat: Tuesday, May 14, 2024 at 1:30 p.m.

BusinesswireMay 9 16:58 ET

ACADIA Pharmaceuticals | 10-Q: Quarterly report

Futu NewsMay 9 15:44 ET · Announcements

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2024 Earnings Call Transcript

Yahoo FinanceMay 9 15:29 ET

ACADIA Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

ACADIA Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMay 9 14:29 ET